#2704 MANAGEMENT OF HAEMODIALYSIS PATIENTS UNDERGOING RADIOACTIVE IODINE THERAPY FOR THYROID CANCER

Abstract Background and Aims Radioactive iodine (RAI) 131I is used in the adjuvant treatment of thyroid carcinoma following thyroidectomy. renally excreted, with reduced clearance patients end-stage kidney disease (ESKD). There are no established protocols for RAI dosing, timing dialysis safety this population [1]. We describe a single-centre experience modified protocol setup haemodialysis (HD) including serum measurements to monitor red marrow toxicity. present outcomes two HD patients. Method A was developed performing post-RAI administration. sessions were performed at 24, 72 144 hours post-treatment. Custom plumbing installed within existing lead-lined infrastructure. Specific considerations made radiation emergency protocols, handling blood samples, nursing education, patient self-cannulation dose-reduction thyrogen pre-treatment. In addition standard dose-rate meter radiation, taken pre- post-HD as more accurate measurement Results The included study aged 41 60 years. Special these anuric state one (bilateral nephrectomy) morbid obesity other. Both had early-stage papillary cancer treated Retained radioactivity measured by shown Figure 1. largest reduction occurred after first session (approximately 60%). highest risk exposure 24 prior session. Pre-and estimated dose be below 0.2Gy (maximum tolerated 2.0Gy2). Radiation received nurses 2. Overall well national regulatory limit 0.5mSv members public. Conclusion produced profile similar controls normal renal function. effect residual function on minimal main determinant ESKD. Non-routine can assess toxicity guide during therapy. Performing 72hrs post- resulted burden accepted radiotoxicity threshold 2Gy [2]. given safely centres appropriate setup.